16 Advanced Solid Tumors Clinical Trials in Seattle, WA (2026)

Q: How do I join a clinical trial in Seattle?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you.

Recruiting Advanced Solid Tumors Studies in Seattle

NCT05584670Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

Seattle, WAPHASE1542 participantsSanofi

View Study Details

NCT06697197Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

Seattle, WAPHASE1413 participantsBristol-Myers Squibb

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Seattle, WAPHASE1405 participantsArriVent BioPharma, Inc.

View Study Details

NCT07160725Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors...

Seattle, WAPHASE1315 participantsBristol-Myers Squibb

View Study Details

NCT06682793Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head a...

Seattle, WAPHASE1240 participantsA2 Biotherapeutics Inc.

View Study Details

NCT07021898Recruiting

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ...

Seattle, WAPHASE1200 participantsErasca, Inc.

View Study Details

NCT05405595Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic s...

Seattle, WAPHASE1186 participantsAdagene Inc

View Study Details

NCT07396584Recruiting

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors....

Seattle, WAPHASE1186 participantsHutchmed

View Study Details

NCT06281678Recruiting

A Study of IBI363 in Subjects with Advanced Solid Malignancies

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies....

Seattle, WAPHASE2178 participantsInnovent Biologics (Suzhou) Co. Ltd.

View Study Details

NCT06625593Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agent...

Seattle, WAPHASE1168 participantsBeOne Medicines

View Study Details

NCT06760819Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to ...

Seattle, WAPHASE2111 participantsBayer

View Study Details

NCT06266299Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors...

Seattle, WAPHASE1101 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT06803680Recruiting

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims ...

Seattle, WAPHASE190 participantsBeOne Medicines

View Study Details

NCT07108114Recruiting

SLV-324 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects w...

Seattle, WAPHASE170 participantsSolve Therapeutics

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

Seattle, WAPHASE163 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07148050Recruiting

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 ...

Seattle, WAPHASE121 participantsSeattle Children's Hospital

View Study Details

About Advanced Solid Tumors Clinical Trials in Seattle

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 16 advanced solid tumors clinical trials recruiting participants in Seattle, WA. These studies are seeking a combined 3,289 participants. Research is being sponsored by Sanofi, Bristol-Myers Squibb, ArriVent BioPharma, Inc. and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Seattle — FAQ

Are there advanced solid tumors clinical trials in Seattle?

Yes, there are 16 advanced solid tumors clinical trials currently recruiting in Seattle, WA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Seattle?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you about next steps.

Are clinical trials in Seattle free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Seattle studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 16 active trials in Seattle are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 16, 2026 from ClinicalTrials.gov